Management will host a conference call at
About
Investor Inquiries: ICR WestwickeMike Piccinino , CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis communications@organo.com
Source:
2024 GlobeNewswire, Inc., source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.465 USD | -1.00% | +5.96% | -39.12% |
May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
Management will host a conference call at
About
Investor Inquiries: ICR WestwickeMike Piccinino , CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis communications@organo.com
Source:
2024 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
-39.12% | 330M | |
+23.92% | 48.09B | |
+47.30% | 40.62B | |
-2.74% | 40.43B | |
-6.95% | 28.36B | |
+7.61% | 24.89B | |
-19.62% | 19.01B | |
+28.86% | 12.09B | |
-0.66% | 11.88B | |
-0.42% | 11.8B |